Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Jea Yu

INSANE: Merck 4 no brainer reasons to buy this dip | Rare Historical Photos

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the market can be unforgiving when companies even slightly miss expectations or forecasts. This is the case with Merck & Co. Inc. (NYSE: MRK), as shares lost over 10% after reporting its fourth quarter of 2024 earnings results.

While the company reported a solid EPS beat by 11 cents as revenue rose 6.8% YoY to $15.62 billion, beating consensus estimates for $15.48 billion, it was the 2025 guidance that shook investor’s confidence. Merck guided EPS of $8.88 to $9.03 versus $9.13 consensus analyst estimates and revenues of $64.1 billion to $65.6 billion, which also fell short of consensus estimates of $67.07 billion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.